Literature DB >> 33877518

Emerging Role of PD-1 in the Central Nervous System and Brain Diseases.

Junli Zhao1, Alexus Roberts2,3, Zilong Wang2, Justin Savage4, Ru-Rong Ji5,6,7.   

Abstract

Programmed cell death protein 1 (PD-1) is an immune checkpoint modulator and a major target of immunotherapy as anti-PD-1 monoclonal antibodies have demonstrated remarkable efficacy in cancer treatment. Accumulating evidence suggests an important role of PD-1 in the central nervous system (CNS). PD-1 has been implicated in CNS disorders such as brain tumors, Alzheimer's disease, ischemic stroke, spinal cord injury, multiple sclerosis, cognitive function, and pain. PD-1 signaling suppresses the CNS immune response via resident microglia and infiltrating peripheral immune cells. Notably, PD-1 is also widely expressed in neurons and suppresses neuronal activity via downstream Src homology 2 domain-containing protein tyrosine phosphatase 1 and modulation of ion channel function. An improved understanding of PD-1 signaling in the cross-talk between glial cells, neurons, and peripheral immune cells in the CNS will shed light on immunomodulation, neuromodulation, and novel strategies for treating brain diseases.
© 2021. Center for Excellence in Brain Science and Intelligence Technology, CAS.

Entities:  

Keywords:  Central nervous system; Immune checkpoint; Immunotherapy; Neurotherapy; PD-1

Mesh:

Substances:

Year:  2021        PMID: 33877518      PMCID: PMC8353059          DOI: 10.1007/s12264-021-00683-y

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.271


  125 in total

Review 1.  Pathobiology of ischaemic stroke: an integrated view.

Authors:  U Dirnagl; C Iadecola; M A Moskowitz
Journal:  Trends Neurosci       Date:  1999-09       Impact factor: 13.837

2.  Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord.

Authors:  Kristina A Kigerl; John C Gensel; Daniel P Ankeny; Jessica K Alexander; Dustin J Donnelly; Phillip G Popovich
Journal:  J Neurosci       Date:  2009-10-28       Impact factor: 6.167

3.  TREK2 expressed selectively in IB4-binding C-fiber nociceptors hyperpolarizes their membrane potentials and limits spontaneous pain.

Authors:  Cristian Acosta; Laiche Djouhri; Roger Watkins; Carol Berry; Kirsty Bromage; Sally N Lawson
Journal:  J Neurosci       Date:  2014-01-22       Impact factor: 6.167

4.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

5.  Cross-talk between programmed death-1 and suppressor of cytokine signaling-1 in inhibition of IL-12 production by monocytes/macrophages in hepatitis C virus infection.

Authors:  Ying Zhang; Cheng J Ma; Lei Ni; Chun L Zhang; Xiao Y Wu; Uday Kumaraguru; Chuan F Li; Jonathan P Moorman; Zhi Q Yao
Journal:  J Immunol       Date:  2011-01-24       Impact factor: 5.422

6.  Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology.

Authors:  Marie-Victoire Guillot-Sestier; Kevin R Doty; David Gate; Javier Rodriguez; Brian P Leung; Kavon Rezai-Zadeh; Terrence Town
Journal:  Neuron       Date:  2015-01-22       Impact factor: 17.173

7.  Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9.

Authors:  Maya Koronyo-Hamaoui; Minhee K Ko; Yosef Koronyo; David Azoulay; Akop Seksenyan; Gilad Kunis; Michael Pham; Joshua Bakhsheshian; Patricia Rogeri; Keith L Black; Daniel L Farkas; Michal Schwartz
Journal:  J Neurochem       Date:  2009-09-24       Impact factor: 5.372

8.  B7-H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: implications for the lesion pathogenesis of multiple sclerosis.

Authors:  Sonja Ortler; Christoph Leder; Michel Mittelbronn; Alla L Zozulya; Percy A Knolle; Lieping Chen; Antje Kroner; Heinz Wiendl
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532

9.  Programmed Death Ligand-1 on Microglia Regulates Th1 Differentiation via Nitric Oxide in Experimental Autoimmune Encephalomyelitis.

Authors:  Jingxia Hu; Hao He; Zhengang Yang; Guangming Zhu; Li Kang; Xiuli Jing; Hai Lu; Wengang Song; Bo Bai; Hua Tang
Journal:  Neurosci Bull       Date:  2016-01-14       Impact factor: 5.203

10.  Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer.

Authors:  Jian Zhang; Huali Zhang; Yongli Luo
Journal:  Med Sci Monit       Date:  2019-02-16
View more
  6 in total

1.  Spatiotemporal Dynamics of the Molecular Expression Pattern and Intercellular Interactions in the Glial Scar Response to Spinal Cord Injury.

Authors:  Leilei Gong; Yun Gu; Xiaoxiao Han; Chengcheng Luan; Chang Liu; Xinghui Wang; Yufeng Sun; Mengru Zheng; Mengya Fang; Shuhai Yang; Lai Xu; Hualin Sun; Bin Yu; Xiaosong Gu; Songlin Zhou
Journal:  Neurosci Bull       Date:  2022-07-05       Impact factor: 5.203

2.  An analgesic peptide H-20 attenuates chronic pain via the PD-1 pathway with few adverse effects.

Authors:  Long Zhao; Hao Luo; Yu Ma; Shengze Zhu; Yongjiang Wu; Muxing Lu; Xiaojun Yao; Xin Liu; Gang Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-25       Impact factor: 12.779

3.  Third Special Issue on Mechanisms of Pain and Itch.

Authors:  Ru-Rong Ji
Journal:  Neurosci Bull       Date:  2022-04-25       Impact factor: 5.271

Review 4.  The Role of Immune Checkpoint Molecules on Macrophages in Cancer, Infection, and Autoimmune Pathologies.

Authors:  Victoria C Brom; Christof Burger; Dieter C Wirtz; Frank A Schildberg
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 7.561

Review 5.  PD-1/PD-L Axis in Neuroinflammation: New Insights.

Authors:  Susanna Manenti; Mario Orrico; Stefano Masciocchi; Alessandra Mandelli; Annamaria Finardi; Roberto Furlan
Journal:  Front Neurol       Date:  2022-06-09       Impact factor: 4.086

6.  Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.

Authors:  Keitaro Kanie; Genzo Iguchi; Hironori Bando; Shin Urai; Hiroki Shichi; Yasunori Fujita; Ryusaku Matsumoto; Kentaro Suda; Masaaki Yamamoto; Hidenori Fukuoka; Wataru Ogawa; Yutaka Takahashi
Journal:  Cancer Immunol Immunother       Date:  2021-05-11       Impact factor: 6.968

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.